Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908773 · ClinicalTrials.gov registry record · Early Phase 1
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
A Early Phase 1 study, sponsored by TransCode Therapeutics.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05908773 is a Early Phase 1 study that has completed, run by TransCode Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT05908773, a Early Phase 1 study, has completed, sponsored by TransCode Therapeutics.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists of 3 parts: a screening period, dosing period, and follow-up period. The estimated total duration of the study is approximately 46 days. Approximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single site.
Interventions
- DRUG TTX-MC138-NODAGA-Cu64
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2023-09-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05908773
The ClinicalTrials.gov registry entry for NCT05908773 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TransCode Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TTX-MC138-NODAGA-Cu64 is the first listed.
NCT05908773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05908773 about?
NCT05908773 is a clinical study titled "A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors". This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 a...
What is the current status of trial NCT05908773?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-04-04. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT05908773?
The interventions under investigation include: TTX-MC138-NODAGA-Cu64 (DRUG).
Who is sponsoring clinical trial NCT05908773?
This trial is sponsored by TransCode Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.